Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026
DOI: 10.1161/atvbaha.125.323916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Kelsey C Muir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI (K.C.M., C.S., M.K., D.D.H.…. Hauptthemen laut MEDLINE: Ventricular Function, Left, Sodium-Glucose Transporter 2 Inhibitors, Myocardial Ischemia, Glycosides. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Ischemic heart disease is the leading cause of mortality and human suffering globally. It often leaves patients with residual symptomatic burden despite current optimized procedural and medical options. Sotagliflozin, a dual SGLT1/2 (sodium-glucose cotransporter 1 and 2) inhibitor, has emerged for its clinically evident ischemic cardiovascular benefits. We hypothesize that sotagliflozin treatment exerts direct myocardial benefits in ischemic heart disease, independent of comorbid conditions. METHODS: Yorkshire swine (n=22) underwent placement of an ameroid constrictor around the left circumflex coronary artery. Following a 2-week period in which the ameroid gradually closes, swine (n=18) were randomized to receive either 400 mg daily sotagliflozin (n=8) or no drug (n=10) for 5 weeks. Afterwards, swine underwent terminal harvest to acquire cardiac functional data with pressure-volume loops, myocardial perfusion by microsphere injection, and ventricular sectioning. To investigate the cellular and tissue-level impact of therapy, histology, immunoblotting, and high-throughput techniques were performed. RESULTS: Sotagliflozin swine had improved ejection fraction, cardiac output, and stroke work compared with no drug ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Brown University, Providence, RI (K.C.M., C.S., M.K., D.D.H., M.R.A., F.W.S.).
- Cardiovascular Research Center, Division of Cardiothoracic Surgery, Rhode Island Hospital, Providence, RI (K.C.M., C.S., R.R., M.K., J.H., D.D.H., M.R.A., F.W.S.).
ORCID-Profile: Kelsey C Muir, Christopher Stone, Riya Reddy, Meghamsh Kanuparthy, Jad Hamze, M Ruhul Abid, Frank W Sellke
Förderung
- NHLBI NIH HHS
- NIH HHS
- NIGMS NIH HHS
- NCRR NIH HHS
Zitieren
APA
Muir, K. C., Stone, C., Reddy, R., Kanuparthy, M., Hamze, J., Harris, D. D., Abid, M. R., & Sellke, F. W. (2026). Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.125.323916
Vancouver
Muir KC, Stone C, Reddy R, Kanuparthy M, Hamze J, Harris DD, et al. Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.125.323916
BibTeX
@article{Muir2026,
author = {Muir, Kelsey C and Stone, Christopher and Reddy, Riya and Kanuparthy, Meghamsh and Hamze, Jad and Harris, Dwight D and Abid, M Ruhul and Sellke, Frank W},
title = {Sotagliflozin Enhances Left Ventricular Function and Myocardial Perfusion in Chronic Myocardial Ischemia Through Metabolic and Redox Remodeling},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
doi = {10.1161/atvbaha.125.323916}
}
EUVIMED